Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673231 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
A Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,240
- Enrollment target
- 20
- Study locations
NCT00673231: Completed Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
NCT00673231 is a Phase 3 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 1,240 participants, below the 3,920-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00673231, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
Primary Outcome
To assess the efficacy of 2.5 mg, 5 mg and 10 mg dapagliflozin compared to placebo as add-on therapy to insulin in improving glycaemic control in participants with type 2 diabetes who have inadequate glycaemic control on ≥ 30 IU injectable insulin daily for at least 8 weeks prior to enrolment, as determined by the change in HbA1c levels from baseline to Week 24, excluding data after insulin up-titration.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Study Locations (20)
Other
- Research Site - Salzburg
- Research Site - Vienna
- Research Site - Pleven
- Research Site - Rousse
- Research Site - Sofia
- Research Site - Varna
California
- Research Site - Fresno
- Research Site - Greenbrae
Illinois
- Research Site - Chicago
- Research Site - Springfield
Texas
- Research Site - Corpus Christi
- Research Site - Dallas
Virginia
- Research Site - Norfolk
- Research Site - Richmond
Georgia
- Research Site - Roswell
Indiana
- Research Site - Indianapolis
Nebraska
- Research Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,240 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
What the finished NCT00673231 record still lists
NCT00673231 is an interventional study that assigns participants to a tested intervention. Its 1,240 participants enrollment target places it among the larger protocols in the corpus, below the 3,920-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00673231 names 20 study sites across 11 states, led by Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00673231 about?
NCT00673231 is a clinical study titled "Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin". This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
What is the current status of trial NCT00673231?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,240 participants. The study started on 2008-04. Estimated completion is 2011-01.
What conditions does trial NCT00673231 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00673231?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00673231?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00673231 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00673231's enrollment target sits among peer trials
1,240 19th of 327 higher than 309 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06368245 · 1,244 participants
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia